New research may be a determining factor for Black multiple sclerosis (MS), who often experience different symptoms than those of other races, when deciding whether or not to get vaccinated.
RELATED: Why Do Black Patients Fare Worse When MS Strikes?
MS patients undergoing a treatment that depletes a type of immune cell that fuels MS attacks still have a strong response to mRNA COVID-19 vaccines, a new study finds.
"The message from this study is clear — it is worthwhile for patients with MS receiving [anti-CD20] treatment to get a COVID-19 vaccine, which will prevent severe illness," researcher E. John Wherry, director of the Penn Institute for Immunology, in Philadelphia says.
Anti-CD20 treatment depletes the B-cells that contribute to the MS attacks. B-cells and T-cells are types of white blood cells that make immune system antibodies.
For the study, Wherry's team measured antibody and T-cell responses in 20 patients with MS who were getting anti-CD20 treatment.
They compared those patients with a group of healthy people.
All of the healthy participants had antibodies following the first dose of an mRNA vaccine (such as Moderna or Pfizer), and the level of antibody increased after the second dose. In patients with MS, however, the antibody response was more varied.
A month after their second vaccine dose, between 50% and 85% had developed
protective responses to SARS-CoV-2.
For those without detectable antibodies, the size of the response was lower and delayed, the researchers found.
"This data not only reveals that patients undergoing anti-CD20 infusions are still able to mount important COVID-19 vaccine responses which are likely to protect from severe illness, but also informs our clinical practices in how we advise patients with MS and other autoimmune disorders on such therapies," researcher Dr. Amit Bar-Or, chief of the division of MS and related disorders at Penn's Perelman School of Medicine says.
MS Made Simple: Here’s How Your Age Will Affect Your Treatment Plan
"For example, knowing that responses are weakest immediately following an anti-CD20 infusion, we can now advise patients to wait a number of months after their therapy to get a COVID-19 vaccine," Bar-Or adds in a university news release.
Because of the limited antibody responses among patients receiving anti-CD20 treatment, they might not be able to kill the virus as quickly before it infects other cells, the researchers say.
As a result, they could be carriers of the virus for a longer period of time.
You should always consult with your healthcare provider about your medical condition, and what is appropriate for you.
Additionally, the CDC has more information about vaccines for immunocompromised people.
